EIF4G1 and hematologic disorder: EIF4G, the target of miR-139-5p repression, is also highly activated in lymphoma cells, specifically diffuse large B-cell lymphoma (DLBCL), pointing to the possibility of miR-139-5p suppression across hematological malignancies [49].